We now report the decreased level of IL-6 in HCC tissues treated by TBK1 antagonist (Supplementary Figure 5D) as well as the TBK1 expression in HCC and tumor stroma (Supplementary Figures 5G, H). Here, IL6 is linked to hepatocellular carcinoma.